Abera Bioscience announces that a scientific article about the company's vaccine technology has been published in the journal npj Vaccines.The study provides new insights into the mechanism of action behind the vaccine candidate Ab-01.12 and shows that intranasal vaccination effectively activates the immune system in the respiratory mucosa and engages both innate and adaptive immune mechanisms at an early stage, according to the company.The results also support the hypothesis that the vaccine can counteract bacterial colonization in mucous membranes, which is central to preventing disease and reducing transmission.